These “educated” osteoblasts express RUNX2/osteocalcin (OCN)/OPN, are negative for IL-6 and α-smooth muscle actin (αSMA), and have new properties where they acquire the capacity to suppress both triple-negative and ER+ breast cancer cell proliferation [153]. The gene discussed is RUNX2; the disease is breast carcinoma.